Jennifer Phipps
CFO, Executive VP & Corporate Secretary

So the total growth was -- in the guide is 29% to 34% year-over-year. Organic represents about 23.5% to 28% growth. So really strong organic growth expected.

Unknown Analyst

And with that guidance change, when we look at the revenue change and EBITDA, the incremental margin was pretty high. So, kind of, help us understand, like what was this incremental, I guess, EBITDA flow-through that kind of comes at this very high margin?

Jennifer Phipps
CFO, Executive VP & Corporate Secretary

Yes. So the first is from a provider standpoint, there was a revenue raise. Volumes are expected to be stronger, and there are also some operational projects that we expect to come online. So associated with that, that tends to have a higher margin profile than the pharmacy side.

Pharmacy, we also do expect volume growth, and we also had both -- so there's benefit from an EBITDA standpoint in pharmacy, both on volume and mix of the drugs, but also additional operational projects that benefit margin that we expect to come online as well.

Unknown Analyst

Right. And you mentioned in the pharmacy, right, this EBITDA flow-through on these volumes and some mix, right? But clearly, when we look at the gross profit per script, grew about 30% year-over-year, very robust growth. So kind of -- can you help us understand -- I know you don't want to specifically put numbers on different items, but a couple of different categories, right, that drove that increase in the gross profit per script. So kind of help us understand the magnitude, like which is the biggest driver versus the smallest driver of that growth?